Document is current
Any future updates will be listed below
-
Authors
Giafaglione, Jenna M. https://orcid.org/0000-0002-1374-5779
Crowell, Preston D.
Delcourt, Amelie M. L.
Hashimoto, Takao https://orcid.org/0000-0002-7205-0897
Ha, Sung Min https://orcid.org/0000-0003-3945-8329
Atmakuri, Aishwarya https://orcid.org/0000-0002-1648-3890
Nunley, Nicholas M.
Dang, Rachel M. A. https://orcid.org/0000-0002-0347-3300
Tian, Mao
Diaz, Johnny A. https://orcid.org/0000-0002-7289-6059
Tika, Elisavet
Payne, Marie C. https://orcid.org/0000-0001-8700-2460
Burkhart, Deborah L. https://orcid.org/0000-0002-7457-6032
Li, Dapei
Navone, Nora M. https://orcid.org/0000-0001-8645-6890
Corey, Eva https://orcid.org/0000-0002-9244-3807
Nelson, Peter S. https://orcid.org/0000-0002-5451-5726
Lin, Neil Y. C.
Blanpain, Cedric
Ellis, Leigh
Boutros, Paul C. https://orcid.org/0000-0003-0553-7520
Goldstein, Andrew S. https://orcid.org/0000-0003-0434-9149
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA237191)
U.S. Department of Defense (HT94252310379)
- License Information
-
More Information
Article History
Received: 25 January 2023
Accepted: 26 September 2023
First Online: 4 December 2023
Competing interests
: P.C.B. sits on the Scientific Advisory Boards of Sage Bionetworks, BioSymetrics Inc. and Intersect Diagnostics Inc. E.C. obtains funding from Genentech, Sanofi, AbbVie, Astra Zeneca, Foghorn Pharmaceuticals, Kronos Bio, MacroGenics, Janssen Research, Bayer Pharmaceuticals, Forma Pharmaceuticals, Gilead and Zenith Epigenetics, and is a consultant of DotQuant. P.S.N. has received consulting fees from Janssen, Merck, Bristol Myers Squib and Venable Fitzpatrick, and received research funding from Janssen for work unrelated to the present study. All other authors declare no competing interests.
